Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SITC 2021 | The role of CRISPR in oncology

Shengqing Gu • 14 Nov 2021
SITC 2021
General

Shengqing Gu, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses the potential role of the CRISPR technology in oncology. In the context of immunotherapy, CRISPR approaches could be used to identify the genes modulating the immune response in cancer. Dr Gu emphasizes on the importance of combining CRISPR with computational biology approaches to make sense of the data obtained with this technology. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.

More from Shengqing Gu

0:50
Increasing MHC Class I expression to potentiate the effects of ICB therapy
Shengqing Gu • 14 Nov 2021

Related Videos

2:03
Biomarker detection for early cancer detection
Robert Rintoul • 19 Apr 2024
0:29
Innovative ctDNA-based liquid biopsy techniques for cancer diagnosis
Alain Thierry • 9 Apr 2024
0:50
Employing fragmentomics as a novel strategy to characterize and detect cancers
Alain Thierry • 9 Apr 2024
1:27
Emerging trials in melanoma: SWOG S1801, OpACIN-neo and PRADO
Christoffer Gebhardt • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals